X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs DR. REDDYS LAB - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA DR. REDDYS LAB TORRENT PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 48.0 27.7 173.2% View Chart
P/BV x 6.5 3.4 190.8% View Chart
Dividend Yield % 0.8 0.8 101.9%  

Financials

 TORRENT PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
DR. REDDYS LAB
Mar-18
TORRENT PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,5502,788 55.6%   
Low Rs1,1441,902 60.1%   
Sales per share (Unadj.) Rs354.7860.8 41.2%  
Earnings per share (Unadj.) Rs40.157.1 70.2%  
Cash flow per share (Unadj.) Rs64.2122.0 52.6%  
Dividends per share (Unadj.) Rs14.0020.00 70.0%  
Dividend yield (eoy) %1.00.9 121.9%  
Book value per share (Unadj.) Rs273.1757.7 36.0%  
Shares outstanding (eoy) m169.22165.91 102.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.82.7 139.4%   
Avg P/E ratio x33.641.1 81.8%  
P/CF ratio (eoy) x21.019.2 109.1%  
Price / Book Value ratio x4.93.1 159.3%  
Dividend payout %34.935.0 99.7%   
Avg Mkt Cap Rs m227,897389,034 58.6%   
No. of employees `00014.723.5 62.5%   
Total wages/salary Rs m11,35332,149 35.3%   
Avg. sales/employee Rs Th4,083.06,070.8 67.3%   
Avg. wages/employee Rs Th772.31,366.6 56.5%   
Avg. net profit/employee Rs Th461.3402.5 114.6%   
INCOME DATA
Net Sales Rs m60,021142,810 42.0%  
Other income Rs m2,9881,552 192.6%   
Total revenues Rs m63,009144,362 43.6%   
Gross profit Rs m13,49323,512 57.4%  
Depreciation Rs m4,08610,772 37.9%   
Interest Rs m3,085788 391.5%   
Profit before tax Rs m9,31013,504 68.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5294,380 57.7%   
Profit after tax Rs m6,7819,468 71.6%  
Gross profit margin %22.516.5 136.5%  
Effective tax rate %27.232.4 83.7%   
Net profit margin %11.36.6 170.4%  
BALANCE SHEET DATA
Current assets Rs m52,623104,984 50.1%   
Current liabilities Rs m52,02268,938 75.5%   
Net working cap to sales %1.025.2 4.0%  
Current ratio x1.01.5 66.4%  
Inventory Days Days12074 160.8%  
Debtors Days Days76104 73.6%  
Net fixed assets Rs m85,016104,385 81.4%   
Share capital Rs m846830 102.0%   
"Free" reserves Rs m45,376124,886 36.3%   
Net worth Rs m46,222125,716 36.8%   
Long term debt Rs m41,11525,089 163.9%   
Total assets Rs m142,432225,443 63.2%  
Interest coverage x4.018.1 22.2%   
Debt to equity ratio x0.90.2 445.7%  
Sales to assets ratio x0.40.6 66.5%   
Return on assets %6.94.5 152.3%  
Return on equity %14.77.5 194.8%  
Return on capital %14.29.7 146.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58072,623 20.1%   
Fx outflow Rs m3,60018,916 19.0%   
Net fx Rs m10,98053,707 20.4%   
CASH FLOW
From Operations Rs m8,94218,030 49.6%  
From Investments Rs m-47,070-14,883 316.3%  
From Financial Activity Rs m34,174-4,440 -769.7%  
Net Cashflow Rs m-3,655-1,236 295.7%  

Share Holding

Indian Promoters % 71.5 25.5 280.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 5.4 130.0%  
FIIs % 12.6 35.3 35.7%  
ADR/GDR % 0.0 18.5 -  
Free float % 8.8 15.3 57.5%  
Shareholders   26,511 75,885 34.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Dec 14, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - ABBOTT INDIA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS